MIAMI, FL/ACCESSWIRE/September 16, 2022/ Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapies and regenerative medicine, today announced that the company will expand into the skin care and hair.
On September 14, 2022, BeautyHealth’s Hydrafacial (NASDAQ:SKIN) announced its new partnership with Organicell to create the first exosome booster on the market for its patented Hydrafacial device. Organicell’s scientific team will work with Hydrafacial to prove the efficacy of how this new booster application can reduce inflammation, increase collagen and increase elastin while extending the benefits of a traditional Hydrafacial.
Organicell CEO Matt Sinnreich said, “This partnership is the first in a long series that we are working on in the area of aesthetics and hair. Hydrafacial is its own market, and we have given them exclusivity for their applications, however, this partnership paves the way for our scientific team to start collecting data that could help prove the effectiveness of our products on hair restoration. and in various topical skincare and aftercare products.
“Extracellular vesicles (EVs) are anti-inflammatory in nature. Our patent-pending process allows us to concentrate up to 600 billion EVs per milliliter which contain over 300 cytokines, chemokines and growth factors. The scientific team from Organicell will investigate how certain characterizations of our extracellular vesicles can be used in hair transplant procedures to speed healing and reduce swelling. They will examine how our products can potentially replace a Platelet Rich Plasma (PRP) procedure. for hair restoration. And our clinical research will collect data to see how our electric vehicles can help reduce wrinkles and the first signs of aging.”
Sinnreich concluded, “This partnership is a great first step into the skincare space. We are honored that Hydrafacial has trusted our scientific team enough to be their partner in this innovative new booster for their incredibly successful business. Now that the door is open, we can conduct the necessary research to prove our thesis on the rest of the applications that we believe the skin and hair care market needs.”
Future press releases and industry updates
Investors interested in receiving periodic press releases and industry updates are encouraged to email [email protected]
About Organicell Regenerative Medicines, Inc.
Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a clinical-stage biopharmaceutical company focused on the development of innovative biological therapies and regenerative medicine. The Company’s proprietary products are derived from perinatal sources and manufactured to retain naturally occurring exosomes, hyaluronic acid and proteins without the addition or combination of any other substance or diluent. To learn more, please visit
About Beauty Health Company
The Beauty Health Company (NASDAQ: SKIN) is a global category building company focused on delivering health and beauty experiences by reinventing our consumers’ relationship with their skin, body and self-confidence. Our flagship brand, Hydrafacial™, created the hydradermabrasion category using a patented Vortex-Fusion delivery system to cleanse, peel, exfoliate, extract, infuse and hydrate skin with proprietary solutions and serums. Hydrafacial™ provides a non-invasive and accessible experience with a powerful community of estheticians, consumers and partners, connecting aesthetics with beauty to democratize and personalize skincare solutions across ages, genders, tones of skin and skin types. Hydrafacial™ is available in over 90 countries with an installed base of nearly 23,000 delivery systems delivering millions of consumer experiences each year. For more information, please visit
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act “), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will”, “believes”, “expects”, “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks and uncertainties, and such expectations may prove to be incorrect. We remind you that actual results may vary significantly due to known and unknown risks and uncertainties, including, but not limited to: potential problems with our financial condition, competition, ability to retain personnel key, the safety, efficacy and acceptance of products, the commercial success of any new product or technology, the success of clinical programs, the ability to retain key customers, our inability to expand sales and distribution channels , laws or regulations affecting our operations, including pricing, reimbursement or access to products, the ability to protect our patents and other intellectual property both domestically and internationally, and other risks and known and unknown uncertainties, including risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the W eb of the SEC (http://www.sec.gov ). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. The specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and expressly disclaims any obligation to update the information contained in this press release.
Investor Relations and Media Relations
Organicell Investor Relations
1-888-963-7881 ext. 701
THE SOURCE: Organicell Regenerative Medicine
See the source version on accesswire.com: